Sunshine Biopharma Inc. also files under SFBM; those filings are included.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
| Date | Insider | Role | Action | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 7, 2026 | Natan David | Director | Grant(A) | 58K | — | $0 |
| Apr 14, 2026 | Natan David | Director | Grant(A) | 100K | — | $0 |
| Mar 4, 2024 | Slilaty Steve N. | Chief Executive Officer, Director, 10% Owner | Buy(P) | 100K | $0.10 | $10K |
| Feb 8, 2024 | Slilaty Steve N. | Chief Executive Officer, Director, 10% Owner | Buy(P) | 20K | $0.10 | $2K |
| Nov 30, 2022 | Sebaaly Camille | CFO/Secretary | Buy(P) | 30K | $0.76 | $23K |
| Jun 3, 2022 | Sebaaly Camille | CFO/Secretary | Buy(P) | 25K | $1.22 | $31K |
| Feb 18, 2022 | Slilaty Steve N. | Chief Executive Officer, Director | Disposed to issuer(D) | 990K | $0.10 | $99K |
| Jan 6, 2021 | Sebaaly Camille | CFO/Secretary, Director | Grant(A) | 20.0M | — | $0 |
| Jan 6, 2021 | Slilaty Steve N. | Chief Executive Officer, Director | Grant(A) | 20.0M | — | $0 |
| Jan 6, 2021 | Merzouki Abderrazzak | Chief Operating Officer, Director | Grant(A) | 20.0M | — | $0 |
| Jun 17, 2020 | Slilaty Steve N. | Chief Executive Officer, Director | Grant(A) | 500K | $0.10 | $50K |
| Dec 31, 2019 | Slilaty Steve N. | Chief Executive Officer, Director | Other(J) | 324K | — | $0 |
| Dec 31, 2019 | Sebaaly Camille | CFO/Secretary, Director | Grant(A) | 324K | — | $0 |
| Dec 19, 2019 | Sebaaly Camille | CFO/Secretary, Director | Grant(A) | 1.3M | — | $0 |
| Dec 19, 2019 | Slilaty Steve N. | Chief Executive Officer, Director | Grant(A) | 1.3M | — | $0 |
| Dec 19, 2019 | Merzouki Abderrazzak | Chief Operating Officer, Director | Grant(A) | 1.3M | — | $0 |
| Oct 20, 2019 | Sebaaly Camille | CFO/Secretary, Director | Grant(A) | 1.1M | — | $0 |
| Oct 20, 2019 | Slilaty Steve N. | Chief Executive Officer, Director | Grant(A) | 1.1M | — | $0 |
| Oct 20, 2019 | Merzouki Abderrazzak | Chief Operating Officer, Director | Grant(A) | 1.1M | — | $0 |
| Sep 11, 2019 | Sebaaly Camille | Secretary, Director, 10% Owner | Grant(A) | 11.0M | — | $0 |
| Sep 11, 2019 | Sebaaly Camille | CFO/Secretary, Director | Grant(A) | 550K | — | $0 |
| Sep 2, 2019 | Merzouki Abderrazzak | Chief Operating Officer, Director | Grant(A) | 13.0M | — | $0 |
| Sep 2, 2019 | Slilaty Steve N. | Chief Executive Officer, Director, 10% Owner | Grant(A) | 13.0M | — | $0 |
| Sep 2, 2019 | Sebaaly Camille | Secretary, Director, 10% Owner | Grant(A) | 13.0M | — | $0 |
| Aug 27, 2018 | Sebaaly Camille | Secretary, Director | Grant(A) | 38.0M | — | $0 |
| Aug 27, 2018 | Slilaty Steve N. | Chief Executive Officer, Director | Grant(A) | 38.0M | — | $0 |
| Aug 27, 2018 | Merzouki Abderrazzak | Chief Operating Officer, Director | Grant(A) | 38.0M | — | $0 |
| Jun 20, 2018 | Sebaaly Camille | Secretary, Director | Grant(A) | 27.0M | — | $0 |
| Jun 20, 2018 | Merzouki Abderrazzak | Chief Operating Officer, Director | Grant(A) | 27.0M | — | $0 |
| Jun 20, 2018 | Slilaty Steve N. | Chief Executive Officer, Director | Grant(A) | 27.0M | — | $0 |
| Apr 22, 2018 | Merzouki Abderrazzak | Chief Operating Officer, Director | Grant(A) | 12.0M | — | $0 |
| Jul 20, 2017 | Merzouki Abderrazzak | Chief Operating Officer, Director | Grant(A) | 14.0M | — | $0 |
| Jul 20, 2017 | Slilaty Steve N. | Chief Executive Officer, Director | Grant(A) | 14.0M | — | $0 |
| Jul 20, 2017 | Sebaaly Camille | Secretary, Director | Grant(A) | 14.0M | — | $0 |
| Dec 6, 2016 | Merzouki Abderrazzak | Chief Operating Officer, Director | Grant(A) | 28.0M | — | $0 |
| Dec 6, 2016 | Slilaty Steve N. | Chief Executive Officer, Director | Grant(A) | 26.0M | — | $0 |
| Dec 6, 2016 | Sebaaly Camille | CFO and Secretary, Director | Grant(A) | 26.0M | — | $0 |
| Oct 10, 2016 | Slilaty Steve N. | Chief Executive Officer, Director, 10% Owner | Other(J) | 136.9M | — | $0 |
| Oct 10, 2016 | Sebaaly Camille | CFO and Secretary, Director, 10% Owner | Other(J) | 129.5M | — | $0 |
| Oct 10, 2016 | Advanomics Corp | 10% Owner | Other(J) | 136.9M | — | $0 |
| Jul 8, 2016 | Slilaty Steve N. | Chief Executive Officer, Director, 10% Owner | Other(J) | 321.3M | — | $0 |
| Apr 22, 2016 | Sebaaly Camille | CFO and Secretary, Director | Grant(A) | 12.0M | $0.01 | $120K |
| Apr 22, 2016 | Slilaty Steve N. | Chief Executive Officer, Director | Grant(A) | 12.0M | $0.01 | $120K |
| Apr 12, 2016 | Slilaty Steve N. | Chief Executive Officer, Director | Buy(P) | 253K | $0.20 | $51K |
| May 27, 2015 | Slilaty Steve N. | Chief Executive Officer, Director, 10% Owner | Buy(P) | 500K | $0.10 | $50K |
| Jan 9, 2015 | Slilaty Steve N. | Chief Executive Officer, Director, 10% Owner | Other(J) | 150K | $0.02 | $3K |
| Jan 9, 2015 | Slilaty Steve N. | Chief Executive Officer, Director, 10% Owner | Other(J) | 1.2M | $0.02 | $24K |
| Sep 4, 2012 | Slilaty Steve N. | Chief Executive Officer, Director, 10% Owner | Other(J) | 2.6M | $0.05 | $130K |
| Dec 21, 2011 | Slilaty Steve N. | Chief Executive Officer, Director, 10% Owner | Conversion(C) | 17.0M | — | $0 |
| Dec 21, 2011 | Slilaty Steve N. | Chief Executive Officer, Director, 10% Owner | Conversion(C) | 17.0M | — | $0 |
Insider transactions sourced from SEC EDGAR Form 4 filings, normalized within minutes of acceptance. "Buy"/"Sell" mark open-market transactions (codes P/S), the tradeable signal. Awards, option exercises and tax-withholding are shown with their raw code. All data is public domain.
Issuer: Sunshine Biopharma Inc., SEC CIK 0001402328. The symbol on a Form 4 is typed by the filer, so this page follows the issuer with the newest filing under SBFM and shows every filing by that issuer (also filed as SFBM).
Coverage: Form 4 filings indexed 2006-01-02 → 2026-09-15. Earlier history is backfilling; this window widens as it deepens.
Programmatic access via the Arkolith API & MCP server (insider.transactions, insider.company).
Connected pages for SBFM